Internal Med Medical News about Satraplatin

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Pazopanib Approved for Advanced Kidney Cancer

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Over-the-Counter Nanotech Test for Prostate Cancer Anticipated

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Satraplatin: leading the new generation of oral platinum agents
Expert Opinion on Investigational Drugs, 11/06/09

Bhargava A et al. – Satraplatin has a favorable toxicity profile, and appears to have clinical activity against a variety of malignancies such as breast, prostate and lung cancer. The oral route of administration and the intermittent schedule makes it very convenient for clinical use. Despite this, a FDA–approved indication has not yet been achieved. The only Phase III trial with satraplatin was conducted in pretreated metastatic castrate–resistant prostate cancer (CRPC), revealing an improvement in progression–free survival but no overall survival benefit. Future development would have to include designing trials in docetaxel–refractory metastatic CRPC, or in other malignancies where cisplatin is of benefit.

<< Previous
How active are American adolescents and have they become less...

Next >>
Safety, tolerability, pharmacokinetics and pharmacodynamics of...